BACKGROUND: Pertussis, also known as whooping cough, is a vaccine-preventable respiratory disease caused by Bordetella pertussis infection, against which Senegalese children are immunized with the diphtheria-tetanus-whole cell pertussis vaccine (DTwP). Seroepidemiology of pertussis has been widely described in industrialized countries, but rare are the studies referring to it in developing countries. METHODS: We conducted a longitudinal survey in Northern Senegal to investigate the epidemiology of B. pertussis by evaluating the IgG antibody (Ab) response against pertussis toxin (PT). A cohort of 410 children aged 1 to 9 from five villages in the Middle Senegal River Valley were followed-up for 18 months. During that period, five visits were made to assess the immunological status of the children. PRINCIPAL FINDINGS: PT-specific IgG responses were significantly different according to age. Until the age of 3, there was a decrease in the Ab response, which then increased in the older groups. Assessment of IgG antibodies to PT (IgG-PT) suggested evidence of recent exposures to the pathogen. Surprisingly, in one of the five villages the average Ab response to PT was very low at all ages during the first 6 months of the study. At the third visit, IgG-PT concentrations peaked to very high levels, to slightly decline at the end of the survey. This indicates an outbreak of B. pertussis, whereas in the other villages a pertussis endemic profile could be observed. CONCLUSIONS: Pertussis is endemic in Northern Senegal despite the introduction of vaccination. The circulation of the bacteria seems to differ between geographic locations and over time. A more complete understanding of the epidemiology of pertussis and its environmental determinants could provide information to adapt vaccination programs.
BACKGROUND: Pertussis, also known as whooping cough, is a vaccine-preventable respiratory disease caused by Bordetella pertussis infection, against which Senegalese children are immunized with the diphtheria-tetanus-whole cell pertussis vaccine (DTwP). Seroepidemiology of pertussis has been widely described in industrialized countries, but rare are the studies referring to it in developing countries. METHODS: We conducted a longitudinal survey in Northern Senegal to investigate the epidemiology of B. pertussis by evaluating the IgG antibody (Ab) response against pertussis toxin (PT). A cohort of 410 children aged 1 to 9 from five villages in the Middle Senegal River Valley were followed-up for 18 months. During that period, five visits were made to assess the immunological status of the children. PRINCIPAL FINDINGS: PT-specific IgG responses were significantly different according to age. Until the age of 3, there was a decrease in the Ab response, which then increased in the older groups. Assessment of IgG antibodies to PT (IgG-PT) suggested evidence of recent exposures to the pathogen. Surprisingly, in one of the five villages the average Ab response to PT was very low at all ages during the first 6 months of the study. At the third visit, IgG-PT concentrations peaked to very high levels, to slightly decline at the end of the survey. This indicates an outbreak of B. pertussis, whereas in the other villages a pertussis endemic profile could be observed. CONCLUSIONS: Pertussis is endemic in Northern Senegal despite the introduction of vaccination. The circulation of the bacteria seems to differ between geographic locations and over time. A more complete understanding of the epidemiology of pertussis and its environmental determinants could provide information to adapt vaccination programs.
Authors: H E de Melker; F G Versteegh; M A Conyn-Van Spaendonck; L H Elvers; G A Berbers; A van Der Zee; J F Schellekens Journal: J Clin Microbiol Date: 2000-02 Impact factor: 5.948
Authors: J M Vincent; J D Cherry; W F Nauschuetz; A Lipton; C M Ono; C N Costello; L K Sakaguchi; G Hsue; L A Jackson; R Tachdjian; P A Cotter; J A Gornbein Journal: Clin Infect Dis Date: 2000-03 Impact factor: 9.079
Authors: Lotte H Hendrikx; Kemal Oztürk; Lia G H de Rond; Reinier H Veenhoven; Elisabeth A M Sanders; Guy A M Berbers; Anne-Marie Buisman Journal: Vaccine Date: 2010-12-25 Impact factor: 3.641
Authors: Fred Zepp; Ulrich Heininger; Jussi Mertsola; Ewa Bernatowska; Nicole Guiso; John Roord; Alberto E Tozzi; Pierre Van Damme Journal: Lancet Infect Dis Date: 2011-05-18 Impact factor: 25.071
Authors: N Guiso; G Berbers; N K Fry; Q He; M Riffelmann; C H Wirsing von König Journal: Eur J Clin Microbiol Infect Dis Date: 2010-11-11 Impact factor: 3.267
Authors: Inonge van Twillert; Jacqueline A M van Gaans-van den Brink; Martien C M Poelen; Kina Helm; Betsy Kuipers; Maarten Schipper; Claire J P Boog; Theo J M Verheij; Florens G A Versteegh; Cécile A C M van Els Journal: PLoS One Date: 2014-01-13 Impact factor: 3.240
Authors: Vincent Kayina; Samuel Kyobe; Fred A Katabazi; Edgar Kigozi; Moses Okee; Beatrice Odongkara; Harriet M Babikako; Christopher C Whalen; Moses L Joloba; Philippa M Musoke; Ezekiel Mupere Journal: PLoS One Date: 2015-04-15 Impact factor: 3.240
Authors: Solohery L Razafimahatratra; Amy Wesolowski; Lala Rafetrarivony; Jean-Michel Heraud; Forrest K Jones; Simon Cauchemez; Richter Razafindratsimandresy; Sandratana J Raharinantoanina; Aina Harimanana; Jean Marc Collard; C J E Metcalf Journal: Epidemiol Infect Date: 2020-11-16 Impact factor: 4.434